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Summary: Protamine sulphate-induced aggregation of soluble fibrin causes an increase of turbidity in the
plasma sample, which can be measured by means of kinetic turbidimetry.
A method was developed which is sufficiently sensitive for the determination of soluble fibrin in plasma
without iüterfering with the sensitivity for fibrinogen. The performance of the assay was studied by analysing
plasma samples with high concentrations of fibrinogen and soluble fibrin at different pH values, at different
concentrations of plasma and protamine sulphate, and using different wavelengths and analysis times.
Measurement of thrombin-induced fibrinogen-fibrin-transformation by the developed turbidimetric method,
gave results that correlated well with the release of fibrinopeptide A.
The new protamine sulphate method for turbidimetric dclcrmination of soluble fibrin is charactcrizcd by its
practicability, rapid availability of reproducible, quantitative results, and ils economy ofreagenls and time in
single and serial analysis. Therefore it seems well-suited for the routine diagnosis of hypercoagulability with
increased fibrinogen turnover.
Introduction measured photometrically by Lipinski in 1968 (17). In
„., . . . -. . . . f .- subsequent modifications of this original protamineFibrin monomers are mtermediate products of the , , - , . - i j i_ - i_ , . ~« . ~ '". j x. ~ t sulphate test the evaluation was simply done by Visualfibnnogen-fibnn-transfonnation, and they form sol- *· *· j · <.- r · j · · r,' ®. 1 - 1 /-· /^ o- estimation and assignation of titres or descnption ofüble fibnn monomer cömplexes in plasma (l, 2). Since ^ .... ^ ^ ^ ^ r ·*-, _, . ^ r . . .A, r turbidity (6, 11 — 13). Due to a lack ofspecifity, espe-the fibnn monomers can aggregate possibly with fi- . „ ^ r./1 , . ' - . rfu&& .ö ^ J cially with regard to fibrinogen, none of the numerousbnnogen and form dimers, tnmers and even ohgo- ,.« .. f , / 4 C 4 0 X* i ui r u · * ur u A \ modifications was successful (14, 15, 18).mers, the term soluble fibrin was established (3,4).
The general aim of our investigation was the sensitive
Increased concentrations of solüble fibrin are an early and quantifiable determination of the soluble fibrin
and sensitive indicator for hypercoagulability with aggregation in a turbidimeter or nephelometer. A
increased fibpnogeä turnover (5—7). preliminary modification of the protamine sulphate
^ . . ,» * , , A-, - i test (19) showed an adequate validity in a preceedingFor routme determination of soluble fibnn, the para- ^Ä ^^, 1000 patient and in these
coagülation test with protamine sulphate was con- no interference b flbrinogen was observed.
sidered practical: After fibrin monomers are released
from their complex bond with fibrinogen, the protam- The intention of the present study was to develop a
ine sulphate supposedly causes Polymerisation of the new turbidimetric method for detection of the pro-
monomers (gelation), or it may possibly induce the tamine sulphate induced aggregation of soluble fibrin
Polymerisation of cömplexes (8 —10). Depending on by systematic modification of the test conditions. This
the cpncentration, either fibrin gel or tiny fibrin method should provide a simple, rapid and quantifi-
strands are forroed (11 — 13), or the fibrinogen can able measurement of soluble fibrin without interfer-
even precipitate (14—16). The resulting turbidity was ence from fibrinogen in plasma.
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Materials and Methods
Citrate plasina was obtaincd by cenlrifugalion (2000g, 10 min)
of blood anticoagulated with sodium cilrate (0.015 mol/1) (1:10
by vol.). Plasma triacylglyceroi and cholestcrol concenlrations
were less lhan 3 g/l. Special anticoagulation was required for
the radioimmunoassay of fibrinopcplidc A and the tests for
fibrin(ogcn) dcgradation products.
Plasma samples with high fibrinogen concentrations (3.5 to 5.4
g/l) were selected from samples taken from healthy blood do-
nors (according to the Standards for blood donor recruitment,
no leukocytosis). Further samples with high fibrinogen concen-
trations (4.0 and 6.5 g/l) were selected from samples from
patients, not seriously ill, and most of them in ambulatory care.
Criteria for selection were normal values in blood coagulation
tests (thromboplastin time, partial thromboplastin time, throm-
bin time, antithrombin III, soluble fibrin-erythrocyte-agglutina-
tion test (20), fibrin(ogen) degradation products).
Plasma samples with high soluble fibrin concentrations were
obtained by incubation of citrate plasma with thrombin (25
NIH units per 1) from Hoffmann-LaRoche, Switzerland, at
30 °C. At 0 and after 0.5, 1.0, 1.5 ... 5, 10, 15, 20, 30 minutes,
thrornbin-induced fibrinogen transformation was terminated by
addition of hirudin (10 000 units per 1) from Pentapharm, Switz-
erland. No clots were visible during the first 10 minutes of
thrombin action.
A serial dilution of soluble fibrin plasma was performed by
diluting this soluble fibrin plasma (thrombin-treated s de-
scribed) in the sarne plasma before thrombin addition.
Standards of soluble fibrin were prepared using desAA-fibrin
(fibrinogen devoid of both fibrinopeptides A) from Biopool,
Sweden, dissolved in l mol/1 NaBr or isotonic NaCl solution.
Serial dilution of these Standards resulted in final concentrations
of 5 to 1000 mg/1 after adding desAA-fibrin Solutions to plasma
(100 μΐ + 900 μΐ).
Methods and reagents of routine diagnosis were used to deter-
mine fibrinogen concentrations (method by Clauss), thrombo-
plastin time, partial thromboplastin time, thrombin time, an-
tithrombin III concentrations and fibrin(ogen) degradation
products (latex agglutination test with a special anticoagulant
from Wellcome, United Kingdom).
Soluble fibrin-erythrocyte-agglutination-test (20) was used for
the determination of soluble fibrin by the agglutination of fibrin
monomer-coated erythrocytes (FM-Test from Boehringer
Mannheim, FRG). If agglutination occurred, the sample was
l :2 diluted with plasma without soluble fibrin.
Fibrinopeptide A RIA: Determination of plasma fibrinopeptide
A was performed radioimmunologically with the FPA-J125-
RIA-Kit (Mallinckrodt, USA) after precipitation of plasma
fibrinogen with bentonite (special anticoagulation with throm-
bin inhibitor).
Turbidimetry of protamine sulphate induced soluble flbrin aggre-
gation: For the determination of soluble fibrin, citrate plasma
and buffer were preincubated; after addition of protamine sul-
phate, the increase in turbidity was measured kinetically in a
turbidimeter. The photometer "EPOS-Analyzer 5060" from Ep-
pendorf (FRG) was suited for a short kinetic analysis; it permits
the measurement of light absorbance in the Hg^spectrum and
is equipped for programmable automatic pipetting of samples,
buffer and protamine sulphate Solutions.
Standard procedure: 40 μΐ citrate plasma and 185 μΐ 0.1 mol/1
Tris buffer (pH 6.5, containing NaCl) were preincubated for
156 seconds at 25 °C; 25 μΐ of a 2 g/l protamine sulphate dilution
were added and after 12 seconds the increase in turbidity was
measured at 334 nm over a timespan of 7 seconds. The result
was calculated from ΔΑ/Δΐ:ΔΑ/ιηίη = (A19s - AI2s) -60/7,
with A0s = addition of protamine sulphate; in printouts the
absorbance values were multiplied by 10000. Analyses were
performed in triplicate, and any value differing from the other
t wo was discarded.
In order to evaluate the test conditions each of the following
paramctcrs was varicd independently: citrate plasma volume
(30, 40 or 50 μΐ), protamine sulphate volume (15, 20 or 30 μΐ
of a protamine sulphate NaCl-solution (2 g/l) diluted from a
10 g/l protamine sulphate solution in 10 g/l benzyl aicohol/H2O
solution from Novo, Danmark), buffer pH value (Tris buffer
with 0.1 mol/1 Tris in 0.15 mol/1 NaCl solution adj sted with
l mol/1 HC1 to pH values 6.5, 7.0, 7.5, 8.0; buffer volume
adj sted to 250 μΐ total volume), wavelength (334, 405, 492,
546, 578 nm). , r
Total volume (250 μΐ), temperature (25 °C), time of plasma-
buffer-preincubation (156 s), protamine sulphate incubation
(12 s) and absorbance measurement (7 s) were kept constant.
The evaluation of the test conditions was performed in samples
with high and low fibrinogen concentfations before and after
thrombin addition (stopped by hirudin) to produce soluble
fibrin.
The kinetics of protamine sulphate-induced soluble fibrin ag-
gregation were investigated in plasma samples with a high
concentration of soluble fibrin or fibrinogen by continuous
measurement of the resulting turbidity after addition of pro-
tamine sulphate. Furthermore, samples with high concentra-
tions of soluble fibrin were incubated with thrombin in excess;
in other series they were treated with streptokinase from Behr-
ing (FRG) and then analysed in the soluble fibrin turbidimetry
again.
In fibrinogen-fibrin-turnover (in vitro induced by thrombin)
soluble fibrin was determined by the turbidimetry, by the eryth-
rocyte agglutination-test and from the release of fibrinopeptide
A. The results were compared and related to the duration of
thrombin action.
Results
Evaluation of the test conditions
Wavelength
Aggregation of soluble fibrin induced by protamine
sulphate causes stronger signal at shorter wave-
lengths, which shows a linear dependence on Hg-
spectrum frequency (fig. 2 a); the same dependence
was shown by spectrophotometry in the continuous
spectrum between 800 and 330 nm (3 minutes after
addition of protamine sulphate).
Kinetics
The continuous increase in turbidity after addition of
protamine sulphate was measured during 140 s in 3
samples with different concentrations of soluble fibrin
(fig. 1). The greatest increase in turbidity ΔΑ/At was
seen immediately after addition of protamine sul-
phate; by using a l: 2 diluted soluble fibrin-sample,
the initial slope was reduced by 50%.
In a plasma sample with a high fibrinogen concentra-
tion (5.5 g/l), an increase in turbidity was also noticed
after addition of protamine sulphate, but distinctly
less than in a sample with a high concentration of
soluble fibrin. The sample was examined before and
after addition of 500 mg/1 desAA-fibrin Standard; in
the sample containing desAA-fibrin the turbidity in-
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Fig. 1. Kinetics of turbidity changes: Continuous measurement
of turbidity after the addition of protamine sulphate to
a plasma sample before (Δ) and after addition of
thrombin (o) and in a sample obtained from a l + l
dilution of both (π); ΔΑ = Ai9s - A12s; AAj = 0.0121,
ΔΑ2 = 0.0066. Clotting in the sample was induced by
addition of thrombin (5000 units/1); after centrifugation
of the sample and addition of protamine sulphate, tur-
bidity was again recorded continuously (D).
crease was about A = 0.0107 from the 12th to the
19th second after addition of protamine sulphate; in
comparison the sample without desAA-fibrin showed
an increase of only A = 0.0006 in the same timespan.
pH Value and concentrations in the assay
In order to optimize the test conditions, ΔΑ/min was
examined in samples with high fibrinogen and fibrin
concentrations (thrombin-induced) in dependence on
the pH value and on plasma- and protamine sulphate
concentration.
Maximal changes in absorbance were obtained upon
buffering the test solution at pH 6.5 to 7.5 (0.1 mol/1
Tris). Above pH 7.0, high fibrinogen concentrations
also caused increasing Signals. Further studies were
therefore performed at pH 6.5 to 7.0 (not shown).
Figure 2 c shows the linear increase in ΔΑ/min after
increasing the concentration of protamine sulphate
and in a set of curves for various djlutions of plasma.
To demonstrate the relation between the specific effect
of protamine sulphate on soluble fibrin and its un-
specific effect on fibrinogen, the Ordinate in figure 2d
shows the quotient of 'turbidity increase in samples
with high concentrations of soluble fibrin' and the
'turbidity increase in samples with high fibrinogen
concentrations'. Above protamine sulphate concen-
trations of 0.2 g/l the fibrinogen sensitivity increased
more than the soluble fibrin sensitivity (fig. 2c—2d).
The increase of turbidity (ΔΑ/min) was not clearly
dependent on the plasma concentration in the test.
Moreover, the curves were dependent on the protam-
ine sulphate concentration (set of curves for 0.12,
0.16, 0.20, 0.24 g/l). At higher protamine suiphate
concentrations, ΔΑ/min increased s the plasma con-
centrations in the test increased.
Sensitivity l linear ity
The results of the turbidimetric method correlated
well with the concentration of soluble fibrin in a
dilution series (r = 0.99, n = 8), using the soluble Fi-
brin plasma and plasma before thrombin treatment s
diluent (fig. 2b); the results were linearly dependent
on soluble fibrin concentrations in the r nge of ΔΑ/
min from 0.010 to 0.150; and there was also a linear
relationship with the serial dilution of desAA-fibrin
in plasma. l g/l desAA-fibrin resulted in a ΔΑ/min of
0.179 and 0.1 g/l in ΔΑ/min of 0.0196. Concentrations
of less than 0.015 g/l desAA-fibrin were not reliably
detected by the new turbidimetric method.
Reproducibility
The Standard deviation of 10 samples with different
concentrations of soluble fibrin, each determined 20
times in triplicate (5 different series with different
laboratory personnel), was less than 5% of the mean
in the r nge of ΔΑ/min from 0.015 to 0.150, and up
to 10% in samples with lower or higher values.
5% of the values in a double determination differed
more than ΔΑ/min > 0.003 and more than 15% from
each other. Additional measurements generally con-
firmed the correspondence of at least 2 values. There-
fore measurements were performed in triplicate and
the median was taken s the result. Within-run coef-
ficients of Variation ranged from 1.7 to 7.4% (tab. 1).



















Addition of excess thrombin (5000 NIH units per 1)
caused an immediate decrease in values obtained by
the soluble fibrin turbidimetry with formation of clots.
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Fig. 2. Evaluation of the test conditions. Standard test condition: preincubation of 40 μΐ citrate plasma with 185 μΐ 0.1 mol/1
Tris-buffer (pH 6.5, containing NaCl) for 156 seconds at 25 °C, addition of 25 μΐ 2 g/l protamine sulphate solution; after
incubation for another 12 seconds the increase in turbidity was measured for 7 seconds in a turbidimeter at 334 nm with·
final calculation of ΔΑ/min. ΔΑ/min in dependence on varied parameters:
(A) Dependence on wavelength of the Hg-spectrum; abscissa is divided reciprocally.
(B) Dependence on concentration of desAA-fibrin in plasma (median, 20 to 80% quantile).
(C) Dependence on protamine sulphate concentration at various dilutions of plasma samples (indicated s fraetion),
samples with high soluble fibrin concentrations (ο, π, Δ) and high fibrin gen concentrations (o).
(D) Dependence of quotient ΔΑ/min for the soluble fibrin sample divided by ΔΑ/min for the fibrin gen sample on
protamine sulphate concentrations at various plasma dilutions (indicated s fractions).
Plasmin (induced by addition of streptokinase) caused
a slower, but fmally complete decrease without gen-
eration of fibrin Strands.
Twenty five percent of the 500 patient plasma samples
with high fibrin gen concentrations (4 — 7 g/l) showed
no elevation of turbidity. In 58% of 34 plasma sam-
ples from obviously healthy persons (blood donors)
with fibrin gen concentrations from 4 to 5.5 g/l, sol-
uble fibrin was not elevated (ΔΑ/min < 0.004); the
other 14 plasma samples yielded only slightly elevated
values.(AA/min < 0.012). More than 90% of normal
subjects with fibrin gen concentrations less than 4 g/l
showed values in the developed method of less than
ΔΑ/min = 0.004.
In a clinical study, healthy persons had distinctly
lower values (mean of ΔΑ/min = 0.0022, n = 45)
than patients from general care wards (mean of ΔΑ/
min = 0.0305, n = 220) and patients from intensive
care wards (mean of ΔΑ/min = 0.0508, n = 598);
intensive care patients suffering from bl od coag la-
tion disorders showed very high values up to ΔΑ/min
of 0.300 (mean of ΔΑ/min = 0.0885, n = 127).
The increase of fibrinopeptide A and the soluble fibrin
turbidimetric values, in dependence on the duration
of the in vitro thrombin ction, is shown in figure 3
(computer-aided curve). The concentrations of fibri-
nopeptide A described an initially linear increase,
rapidly attaining high values. The results of the sol-
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Fig. 3. Comparison of the results from soluble fibrin turbidi-
metry (o) and fibrinopeptide A RIA (B) in dependence
on the duration of thrombin action in the plasma sam-
ples (computer-aided curve fitting).
ble fibrin turbidimetry exhibited a sigmoid curve
with an initial smaller and then larger increase and a
final decline. After 8 minutes both curves ended in a
plateau; high plasma concentrations persisted for the
next 20 minutes. Finally the soluble fibrin turbidi-
metry values decreased slowly, producing visible thin
fibrin Strands.
The curve for the 2 methods was easily reproducible
during 8 test series in which fibrinogen transformation
was induced in various ways; only the initial slope
differed and consequently the plateau with maximal
values.
The comparison of turbidimetry and erythrocyte-^ag-
glutination test in the determination of soluble fibrin,
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Fig. 4. Comparison of the determination of soluble fibrin by
the turbidimetric method (·) and by the erylhrocyte^
agglutination-test (φ) in dependence on the duration
of tbrombin action in plasma samples (^ = positive
erythrocyte agglutination test in l: l, l :2, l :4 or l :8
diluted plasma samples, ̂  = slight or non-reproducible
agglutination).
Discussion
Soluble fibrin is an early and sensitive indicator of
hypercoagulability with increased fibrinogen turnover
(5 — 7). For routine soluble fibrin diagnosis a method
has been developed by systematic modifications of
the test conditions. This method allows an adequately
sensitive and quantitative determination of soluble
fibrin by means of protamine sulphate-induced ag-
gregation of soluble fibrin without interference from
fibrinogen; the test can be performed simply and
rapidly.
Evaluation of the test conditions
Light scattering
Light is diffusely reflected in colloidal Solutions; ne-
phelometers detect scattered light directly, turbidi-
meters indirectly through loss of intensity. Although
the nephelometer tends to be more sensitive at low
turbidity, the present turbidimetric method yields
more sensitive and reproducible results, through fully
automatic analysis and precise kinetic measurements,
than preliminary experiments with a laser-nephelo-
meter (19). Both turbidimetry and nephelometry allow
quantitative measurements, and they are considerably
more sensitive than visual estimations, which are eval-
uated subjectively in titres, or only descriptively.
Wavelength
In spectrophotometry the aggregation of soluble fi-
brin causes a stronger signal at shorter wavelengths
apparently following Raleigffs law of light scattering
(A = k χ frequency). Thus all further experiments
were performed at 334 nm.
Recent kinetic investigations of fibrin aggregation
were^also done at short wavelengths (21—23). In
coritrast, measurement at 610 nm s recommended
by Lipinski (17) decreased the sensitivity. Turbidime-
try of clotting in routine diagnostic tests is usually
recorded at 550 nm.
Kinetics
The continuous measurement of protamine sulphate-
induced turbidity (ΔΑ/At) showed the greatest in-
crease immediately after addition of protamine sul-
phate. The initial velocity was proportional to soluble
fibrin concentrations in plasma (fig. 1), s already
shown by Latallo in kinetic investigations of fibrin
Polymerisation (21). Thus further measurements were
performed with both incubation (12 s) and measure-
ment (7 s) times s short s possible (limited by the
apparatus). This yields a high rate of sample analyses
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(30 seconds per triple measurement). Moreover the
short timing is important to avoid disturbing influ-
ences of fibrinogcn.
Interpolation of 6 single values for each measurement
without any movement of the cuvette in the beam
results in good reproducibility, in spite of the ex-
tremely short time of measurement. The initial tur-
bidity of the plasma sample does not affect the results
during kinetic measurements. Earlier studies used end-
point measurements after 5 — 10 minutes or visual
estimations 15 — 30 minutes after addition of prot-
amine sulphate (11, 12, 24-26). In some studies ad-
ditional controls were performed after 24 hours, in
order to avoid false positive results through precipi-
tation of fibrinogen (11, 13).
pH-value, protamine sulphate concentrations and
plasma fractions were varied in order to establish
optimal test conditions, äs in earlier studies of this
kind(12, 13, 19,21,24,27).
Good results were obtained at pH 6.5 — 7.0. Buffers
other than Tris, such äs phosphate or PIPES Solutions,
all tested in the same manner, resulted in less soluble
fibrin sensitivity or a greater fibrinogen influence.
Using 0.1 mol/1 Tris at pH 6.5, the final mixture after
protamine sulphate and plasma addition resulted in
pH 6.7 to 6.8.
An acid pH value is intended to avoid a spontaneous
Polymerisation of soluble fibrin (21, 26). A pH value
between 5.8 — 7.0 leads to lateral polymerisation of
soluble fibrin, which produces thick fibrils and there-
fore a photometrically well detectable turbidity (23,
27). Only a few authors have used pH values outside
this ränge (14, 27).
Protamine sulphate concentrations ofO.2 g/1 were suit-
able. Several other authors have used protamine sul-
phate concentrations up to 2 g/l (14, 25), and the
effect of such concentrations on fibrinogen precipi-
tation has been discussed controversially (10, 11, 15,
24, 29). Gurewich also used final protamine sulphate
concentrations of 0.2 g/l or less in order to avoid
fibrinogen precipitation (11). Gurewich's serial dilu-
tion test with protamine sulphate concentrations of
0.5—0.06 g/l is known to be a reliable and sensitive,
but time consuming protamine sulphate test for the
detection of soluble fibrin (6, 30). Even though pro-
tamine sulphate is a biological product, another prep-
aration with protamine sulphate from Sigma (USA)
performed identically.
In contrast to the linear dependency of the turbidity
increase on soluble fibrin concentration in plasma (fig.
2 b), there was no clear cut dependency of the turbidity
change /min on the plasma fraction in the final
test mixture (not shown); an increase of /min in
dependence on plasma concentration was noticed only
in the presence of higher concentrations of protamine
sulphate. The observation that a plasma concentra-
tion of 24% did not yield a two fold greater increase
in turbidity than a plasma concentration of 12%
might be due to the fact that not only soluble fibrin
is diluted but all plasma proteins,· and albumin för
example is said to have an inhibitory effect on prot-
amine sulphate. A plasma fraction of 0.20 in the test
provided better results than concentrations of 50 to
90% äs required for visual estimations by other au-
thors (11, 12,24-26).
In conclusion, wheri compared with fonner modifica-
tions with visual estimations, this new methöd for the
detection of protamine sulphate^induced aggregation
of soluble fibrin in a turbidimeter provides low pro-
tamine sulphate and plasma concentrations; it is char-
acterized by a kinetic measurement over a short tirne
period, also with a short incubation time. An ade-
quately sensitive determination of soluble fibrin with^
out interference from plasma fibrinogen was possible
only under these specific test conditions.
Specificity
The in vitro thrombin-induced fibrinogen-fibrin turn-
over was detected equally well by fibrinopeptide A
RIA and soluble fibrin turbidimetry. The values ob-
tained with both methods rose in dependence on the
thrombin action up to a plateau (fig. 3). A small delay
in the increase of turbidimetric values may be due to
a lack of detectable aggregation of soluble fibrin at
very low concentrations of soluble fibrin.
Apart from the correlation with the solüble fibrin-
erythrocyte-agglutination test, in other in vitro studies
the results of the turbidimetry correlated well (n = 51,
r = 0.96) with the immunological determination of
soluble fibrin (31, 32), and (n = 36, r = 0.94) with
the soluble fibrin determined by the tissue plasmino-
gen activator test (31, 33). In addition to this corre-
lation with the immunological and the functional test,
experiments with streptokinase and thrombin sup-
ported the assumption that the turbidity is caused by
a clottable fibrinogen derivative.
The absence of interference by fibrinogen was dem-
onstrated by using plasma samples, which provided
normal values in the newly developed turbidimetric
methöd in spite of high fibrinogen concentrations up
to 6.5 g/l. Nevertheless, high turbidimetric-values were
more freqüent at high fibrinogen concentrations, thus
supporting fonner assumptions on fibrinogen
over (1).
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The influence of plasma proteins, in particular of
fibrin(ogen) degradation products (29), plasma lipids
and drugs has not yet been elucidated completely; late
fibrin(ogen) degradation products apparently do not
cause positive results, whereas early fibrin(ogen) de-
gradation products are supposed to be detected; D-
dimers do not seem to result in' false positive values.
Application of the new turbidimetric method
The reproducibility of the results was adequate (tab.
1). Triplicate measurements were performed in order
to eliminate values differing from the other two; these
were possibly due to the small volume and short time
necessary. In routine diagnosis, the median was taken
äs the result. In spite of the short measuring time of
7 seconds, high reproducibility is obtained by the fully
automatic analysis procedure with exact pipetting and
sensitive optical measurements.
The analytical procedure is simple and can also be
performed by untrained laboratory personnel with a
minimum of labour. Soluble fibrin results could be
obtained more simply, reliably and quickly than the
fibrinopeptide A RIA results.
The high rate of sample throughput, the very low cost
of reagents (less than l % of Quick test) and small
amount of plasma required are all criteria, which help
to make this test economical, an important require-
ment for routine diagnosis.
In conclusion, the practicability and rapid availability
of reproducible quantitative results are important cri-
teria for the application of the newly developed tur-
bidimetric method in determination of soluble fibrin
especially in the routine diagnosis of hypercoagula-
bility with an increased fibrinogen turnover.
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